Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer

American Journal of Clinical Nutrition

Volumn 102, Issue 1, 2015, Pages 109-114

  Webb, Penelope M ^a,b   De Fazio, Anna ^c   Protani, Melinda M ^a,b   Ibiebele, Torukiri I ^a   Nagle, Christina M ^a   Brand, Alison H ^c   Blomfield, Penelope I ^d   Grant, Peter ^e   Perrin, Lewis C ^b   Neale, Rachel E ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL HOBART HOSPITAL   (Australia)

^e MERCY HOSPITAL FOR WOMEN   (Australia)

Author keywords

Ovarian cancer; Overall survival; Progression free survival; Serum 25 hydroxyvitamin D; Vitamin D status

Indexed keywords

25 HYDROXYVITAMIN D; CARBOPLATIN; PACLITAXEL; 25-HYDROXYVITAMIN D; BIOLOGICAL MARKER; VITAMIN D;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; BODY MASS; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MEDICAL RECORD; MIDDLE AGED; OVARY CANCER; TIME OF DEATH; ADOLESCENT; ANALOGS AND DERIVATIVES; AUSTRALIA; BLOOD; LIFESTYLE; MORTALITY; OVARIAN NEOPLASMS; PROGNOSIS; QUESTIONNAIRE; RISK FACTOR; SOCIOECONOMICS; SURVIVAL RATE; TUMOR RECURRENCE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AUSTRALIA; BIOLOGICAL MARKERS; BODY MASS INDEX; DIETARY SUPPLEMENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIFE STYLE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROGNOSIS; QUESTIONNAIRES; RISK FACTORS; SOCIOECONOMIC FACTORS; SURVIVAL RATE; VITAMIN D; YOUNG ADULT;

EID: 84937435890     PISSN: 00029165     EISSN: 19383207     Source Type: Journal    
DOI: 10.3945/ajcn.114.102681     Document Type: Article

References (23)

1. Samuel S, Sitrin MD. Vitamin D's role in cell proliferation and differentiation. Nutr Rev 2008;66:S116-24.
2. International Agency for Research on Cancer (IARC). Vitamin D and cancer. IARC Working Group Reports. Lyon (France): IARC; 2008.
3. Autier P, Boniol M, Pizot C, Mullie P. Vitamin D status and ill health: a systematic review. Lancet Diabetes Endocrinol 2014;2:76-89.
4. Villena-Heinsen C, Meyberg R, Axt-Fliedner R, Reitnauer K, Reichrath J, Friedrich M. Immunohistochemical analysis of 1,25-dihydroxyvitamin-D3-receptors, estrogen and progesterone receptors and Ki-67 in ovarian carcinoma. Anticancer Res 2002;22:2261-7.
5. Garland CF, Mohr SB, Gorham ED, Grant WB, Garland FC. Role of ultraviolet B irradiance and vitamin D in prevention of ovarian cancer. Am J Prev Med 2006;31:512-4.
6. Jiang F, Bao J, Li P, Nicosia SV, Bai W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the downregulation of telomerase. J Biol Chem 2004;279:53213-21.
7. ZhengW, Danforth KN, Tworoger SS, Goodman MT, Arslan AA, Patel AV, McCullough ML, Weinstein SJ, Kolonel LN, Purdue MP, et al. Circulating 25-hydroxyvitamin D and risk of epithelial ovarian cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010;172:70-80.
8. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: circulating vitamin D and ovarian cancer risk. Gynecol Oncol 2011; 121:369-75.
9. Rose AA, Elser C, Ennis M, Goodwin PJ. Blood levels of vitamin D and early stage breast cancer prognosis: a systematic review and metaanalysis. Breast Cancer Res Treat 2013;141:331-9.
10. Mohr SB, Gorham ED, Kim J, Hofflich H, Garland CF. Meta-analysis of vitamin D sufficiency for improving survival of patients with breast cancer. Anticancer Res 2014;34:1163-6.
11. Toriola AT, Nguyen N, Scheitler-Ring K, Colditz GA. Circulating 25-hydroxyvitamin D (25-OHD) levels and prognosis among cancer patients: a systematic review. Cancer Epidemiol Biomarkers Prev 2014; 23:917-33.
12. Walentowicz-Sadlecka M, Grabiec M, Sadlecki P, Gotowska M, Walentowicz P, Krintus M, Mankowska-Cyl A, Sypniewska G. 25(OH)D3 in patients with ovarian cancer and its correlation with survival. Clin Biochem 2012;45:1568-72.
13. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
14. Merritt MA, Green AC, Nagle CM,Webb PM. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer. Int J Cancer 2008;122:170-6.
15. Textor J, Hardt J, Knuppel S. DAGitty: a graphical tool for analyzing causal diagrams. Epidemiology 2011;22:745.
16. Daly RM, Gagnon C, Lu ZX, Magliano DJ, Dunstan DW, Sikaris KA, Zimmet PZ, Ebeling PR, Shaw JE. Prevalence of vitamin D deficiency and its determinants in Australian adults aged 25 years and older: a national, population-based study. Clin Endocrinol (Oxf) 2012;77: 26-35.
17. Mezawa H, Sugiura T, Watanabe M, Norizoe C, Takahashi D, Shimojima A, Tamez S, Tsutsumi Y, Yanaga K, Urashima M. Serum vitamin D levels and survival of patients with colorectal cancer: posthoc analysis of a prospective cohort study. BMC Cancer 2010;10:347.
18. Cho M, Peddi PF, Ding K, Chen L, Thomas D, Wang J, Lockhart AC, Tan B, Wang-Gillam A. Vitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma. J Transl Med 2013;11:206.
19. Tretli S, Schwartz GG, Torjesen PA, Robsahm TE. Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. Cancer Causes Control 2012;23:363-70.
20. Tretli S, Hernes E, Berg JP, Hestvik UE, Robsahm TE. Association between serum 25(OH)D and death from prostate cancer. Br J Cancer 2009;100:450-4.
21. Field S, Elliott F, Randerson-Moor J, Kukalizch K, Barrett JH, Bishop DT, Newton-Bishop JA. Do vitamin A serum levels moderate outcome or the protective effect of vitamin D on outcome from malignant melanoma? Clin Nutr 2013;32:1012-6.
22. Holt SK, Kolb S, Fu R, Horst R, Feng Z, Stanford JL. Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol 2013;37:666-70.
23. Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, Chan M, Leake S, Karpavicius B, Haynes S, et al. Serum 25-hydroxyvitamin D3 levels are associated with Breslow thickness at presentation and survival from melanoma. J Clin Oncol 2009;27:5439-44.